Innate Pharma FY2026 EPS Estimate Reduced by HC Wainwright

Innate Pharma S.A. Sponsored ADR (NASDAQ:IPHA) – Equities researchers at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for shares of Innate Pharma in a research note issued on Monday, August 10th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of ($0.79) for the year, down from their previous estimate of ($0.65). HC Wainwright has a “Buy” rating and a $7.00 price target on the stock. The consensus estimate for Innate Pharma’s current full-year earnings is ($0.65) per share. HC Wainwright also issued estimates for Innate Pharma’s FY2027 earnings at ($0.59) EPS, FY2028 earnings at ($0.15) EPS, FY2029 earnings at $0.23 EPS and FY2030 earnings at $0.58 EPS.

Other equities research analysts have also issued reports about the stock. UBS Group reaffirmed a “buy” rating on shares of Innate Pharma in a report on Tuesday. Citigroup raised shares of Innate Pharma from a “buy” rating to an “outperform” rating in a report on Tuesday. Leerink Partners upgraded shares of Innate Pharma from a “market perform” rating to an “outperform” rating and set a $4.00 target price for the company in a research report on Tuesday. Finally, Weiss Ratings raised shares of Innate Pharma from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday, June 26th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.33.

Innate Pharma Price Performance

NASDAQ IPHA opened at $2.15 on Wednesday. Innate Pharma has a 12 month low of $1.17 and a 12 month high of $2.62. The stock’s 50 day moving average is $1.80 and its 200 day moving average is $1.67.

Hedge Funds Weigh In On Innate Pharma

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Millennium Management LLC purchased a new position in Innate Pharma during the 4th quarter valued at approximately $36,000. OLD Mission Capital LLC bought a new stake in Innate Pharma in the 4th quarter worth approximately $50,000. Finally, Jane Street Group LLC purchased a new stake in shares of Innate Pharma during the 4th quarter worth approximately $162,000. 0.16% of the stock is owned by institutional investors.

About Innate Pharma

Innate Pharma SA is a clinical-stage biotechnology company specializing in the discovery and development of antibody-based therapies that harness the body’s innate immune system to combat cancer. Founded in 1999 and headquartered in Marseille, France, the company pioneers novel monoclonal antibodies designed to activate natural killer cells and macrophages, offering a complementary approach to existing immuno-oncology treatments.

The company’s lead program, monalizumab, targets the NKG2A immune checkpoint receptor and is being developed in collaboration with AstraZeneca.